Quarterly report pursuant to Section 13 or 15(d)

Unaudited Condensed Statements of Operations

v3.22.1
Unaudited Condensed Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Operating expenses:    
Research and development $ 16,289 $ 11,618
General and administrative 3,349 3,469
Total operating expenses 19,638 15,087
Loss from operations (19,638) (15,087)
Other income (expense)    
Interest income 73 134
Interest expense (230) (4)
Total other income (expense) (157) 130
Net Loss $ (19,795) $ (14,957)
Net loss per common share outstanding, basic $ (0.20) $ (0.19)
Net loss per common share outstanding, diluted $ (0.21) $ (0.19)
Weighted average number of common shares outstanding, basic 97,914,916 80,466,049
Weighted average number of common shares outstanding, diluted 94,068,514 80,466,049